Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 427 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06678828Enrolling by invitation
Testing a new blood test for prostate cancer risk
This study is testing a new blood test, ClarityDX Prostate, to see if it can help doctors better decide who needs a biopsy. It is for men who have been referred to a urologist because there is a suspicion of prostate cancer but who have not been diagnosed yet.
Calgary, AlbertaAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT04751435Recruiting
Genetic testing education for cancer patients of diverse backgrounds
This study tests new educational materials about genetic testing for cancer patients. It aims to find the best ways to explain genetic testing to people from different backgrounds, especially Black, Latino, and non-Latino non-Black communities.
Brooklyn, New YorkAges 18 years+ - NCT06111781RecruitingPhase 2
Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
New Haven, ConnecticutAges 18 years+ - NCT07710807Recruiting
Comparing two prostate biopsy methods
This trial compares two ways to take a prostate biopsy (through the rectum or through the skin between the scrotum and anus) to see which is more accurate. Men with suspicious MRI findings (PI-RADS 3, 4, or 5) who haven't had prostate cancer before may be eligible.
Ankara, YenimahalleAges 50–75 - NCT06067269RecruitingPhase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer
This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.
Los Angeles, CaliforniaAges 18 years+ - NCT05958082Recruiting
Genetic testing education for Black men with prostate cancer
This study tests whether educational support helps Black men with high-risk prostate cancer complete genetic testing. It may make it easier to get genetic results that can guide care for you and your family.
Detroit, MichiganAges 18 years+ - NCT03079323RecruitingPhase 2
Radiation before or after surgery for prostate cancer spread to lymph nodes
This Phase 2 trial studies whether giving planned radiation to certain lymph node areas (para-aortic/“PART”) after surgery helps people whose prostate cancer has spread to lymph nodes (pN1). You would be screened after a specific lymph node surgery (ePLND) to see if you match their situation, then receive the trial’s radiation plan and follow-up.
LeuvenAges 18 years+ - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Birmingham, AlabamaAges 21 years+ - NCT03327675Recruiting
PET imaging test to plan personalized prostate cancer treatment
This trial tests a high-precision scan that uses a prostate cancer marker to show where cancer may be. The goal is to use the scan results to better plan treatment, especially around surgery and lymph nodes, in certain patients with prostate cancer.
LeuvenAges 18 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Gilbert, ArizonaAges 18 years+ - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03789253Recruiting
Tracking genetic changes as low-risk prostate cancer becomes riskier
This study looks for genes and biological pathways that may explain why some men’s prostate cancer grows from low risk to higher risk. You may be followed using planned prostate biopsies after an initial low-risk diagnosis managed with active surveillance.
TaipeiAges 40–100 - NCT03802851Recruiting
Laser procedure before radiation for prostate cancer symptoms
This trial looks at whether doing a prostate “laser procedure” (called HoLEP) before starting radiation and hormone therapy can improve severe urinary symptoms and reduce urine retention problems. It is for people with prostate cancer who are planning radiation plus hormone treatment and who have significant bladder/urinary trouble.
Kansas City, KansasAges 18 years+ - NCT03833921RecruitingPhase 2
Testing abiraterone and prednisone for metastatic prostate cancer by race
This trial studies how well abiraterone (a hormone-blocking medicine) plus prednisone (a steroid) works in people with metastatic, hormone-sensitive prostate cancer. It also looks at whether results differ by race/ethnicity and other health factors.
Houston, TexasAges 18 years+ - NCT03893929Recruiting
Test new markers to help diagnose prostate cancer
This study looks for new biological markers in men to improve how prostate cancer is diagnosed and followed. If you have signs that might be prostate cancer, your tests may help researchers find better clues for future care.
ShatinAges 18 years+ - NCT04287088Recruiting
MRI plus shared decisions to help diagnose prostate cancer
This study looks at using a special prostate MRI (bpMRI) along with a risk-based shared decision process to guide diagnosis. It may help patients and clinicians decide on next steps using MRI results and individual risk.
JyväskyläAges 18 years+ - NCT04478851Recruiting
Exercise program to help people live well with cancer
This study offers an exercise program meant to help people with cancer improve how they live day to day. It may fit you if you are getting treatment now, starting soon, or finished within the last 5 years and can safely do mild activity.
Calgary, AlbertaAges 18–100 - NCT04543799Recruiting
Sleep quality study in prostate and early breast cancer patients
This trial studies how sleep quality changes while people with prostate cancer or early breast cancer receive standard treatments. It may help doctors understand which treatment factors affect sleep and identify who might benefit from support for sleep problems.
BellinzonaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04612907Recruiting
Radiation timing options for low-burden metastatic prostate cancer
This study compares different radiation schedules to the main prostate tumor in men with low-burden metastatic (spread) hormone-sensitive prostate cancer. It may help find a radiation timing approach that controls the cancer while balancing side effects.
UmeåAges 18 years+ - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT04654338RecruitingPhase 2/Phase 3
Two types of targeted radiation for favorable prostate cancer
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
Toronto, OntarioAges Any age
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 427 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.